Compare Adaptive Biotechnologies Corp (ADPT) vs RLX Technology Inc (RLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs RLX Technology Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while RLX Technology Inc trades at $1.98 (market cap $2.32B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and RLX Technology Inc pays a 5.26% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | RLX | |
|---|---|---|
Market Cap | $3.33B | $2.32B |
Sector | Health | Technology |
52-Week High | $22.37 | $2.73 |
52-Week Low | $10.24 | $1.79 |
Enterprise Value | $3.19B | $955.96M |
Dividend Yield | — | 5.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
RLX stock trades at $1.96, up 1.55% today, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported strong 2025 results with $3.62B revenue and $922M net income, though recent quarters have missed EPS expectations. Positive news highlights international expansion and a cash-rich, debt-free balance sheet, with JPMorgan increasing its stake significantly in Q3 2025.
Outlook is cautiously optimistic given solid profitability and industry growth potential, but risks include regulatory scrutiny in the vaping sector and consistent earnings misses. The sole analyst coverage recommends Hold, reflecting balanced risk-reward amid high cash flows but uncertain near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
